{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T08:01:54Z","timestamp":1764403314175},"reference-count":11,"publisher":"Japanese Circulation Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2024,2,22]]},"DOI":"10.1253\/circj.cj-24-0063","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T22:15:42Z","timestamp":1706739342000},"page":"380-381","source":"Crossref","is-referenced-by-count":1,"title":["Unapproved Dose of Direct Oral Anticoagulants for Venous Thromboembolism\u3000\u2015 Right or Wrong? \u2015"],"prefix":"10.1253","volume":"88","author":[{"given":"Shiro","family":"Adachi","sequence":"first","affiliation":[{"name":"Department of Cardiology, Nagoya University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Adachi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Nakano","sequence":"additional","affiliation":[{"name":"Center for Advanced Medicine and Clinical Research, Department of Advanced Medicine, Nagoya University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Trujillo-Santos J, Di Micco P, Dentali F, Douketis J, Diaz-Peromingo JA, Nunez MJ, et al. Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens. <i>Thromb Haemost<\/i> 2017; 117: 382\u2013389.","DOI":"10.1160\/TH16-07-0494"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Angchaisuksiri P, Goto S, Farjat AE, Fryk H, Bang SM, Chiang CE, et al. Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE. <i>Thromb Res<\/i> 2021; 201: 63\u201372.","DOI":"10.1016\/j.thromres.2021.02.024"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Nakamura M, Yamada N, Asamura T, Shiosakai K, Uchino K. Safety and effectiveness of edoxaban in Japanese venous thromboembolism patients: Final analysis of one-year follow-up data from a Japanese postmarketing observational study (ETNA-VTE-Japan). <i>Circ Rep<\/i> 2020; 2: 192\u2013202.","DOI":"10.1253\/circrep.CR-19-0127"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. <i>N Engl J Med<\/i> 2017; 376: 1211\u20131222.","DOI":"10.1056\/NEJMoa1700518"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. <i>N Engl J Med<\/i> 2013; 368: 699\u2013708.","DOI":"10.1056\/NEJMoa1207541"},{"key":"6","unstructured":"6. REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism (RENOVE). https:\/\/clinicaltrials.gov\/study\/NCT03285438 (accessed January 16, 2024)."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Okumura K, Akao M, Yoshida T, Kawata M, Okazaki O, Akashi S, et al. Low-dose edoxaban in very elderly patients with atrial fibrillation. <i>N Engl J Med<\/i> 2020; 383: 1735\u20131745.","DOI":"10.1056\/NEJMoa2012883"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Yamashita Y, Fukasawa T, Takeda C, Takeuchi M, Ono K, Kawakami K. Clinical characteristics and outcomes of patients with venous thromboembolism receiving edoxaban in the real world. <i>Circ J<\/i> 2024; 88: 371\u2013379.","DOI":"10.1253\/circj.CJ-23-0818"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Koretsune Y, Yamashita T, Kimura T, Fukuzawa M, Abe K, Yasaka M. Short-term safety and plasma concentrations of edoxaban in Japanese patients with non-valvular atrial fibrillation and severe renal impairment. <i>Circ J<\/i> 2015; 79: 1486\u20131495.","DOI":"10.1253\/circj.CJ-14-0942"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Couturaud F, Sanchez O, Pernod G, Mismetti P, Jego P, Duhamel E, et al. Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: The PADIS-PE randomized clinical trial. <i>JAMA<\/i> 2015; 314: 31\u201340.","DOI":"10.1001\/jama.2015.7046"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Nakano Y, Adachi S, Nishiyama I, Yasuda K, Imai R, Yoshida M, et al. Usefulness of a refined computed tomography imaging method to assess the prevalence of residual pulmonary thrombi in patients 1 year after acute pulmonary embolism: The Nagoya PE study. <i>J Thromb Haemost<\/i> 2022; 20: 888\u2013898.","DOI":"10.2139\/ssrn.4133625"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/88\/3\/88_CJ-24-0063\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T03:13:20Z","timestamp":1708744400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/88\/3\/88_CJ-24-0063\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-24-0063","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]},"article-number":"CJ-24-0063"}}